Pliant Q2 Loss Narrows, Cash Runway Extended to H2 2028 as Oncology Pipeline Advances
PLRX is trading near its 52-week low of $1.03 (1.9% above the low).
Summary
Pliant Therapeutics reported a narrower Q2 loss and extended its cash runway into H2 2028, while its lead oncology program showed encouraging early progress.
Key Events · Earnings and Guidance · PLRX
-
Q2 Loss Narrows Sharply
Net loss fell to $22.4M from $43.3M in Q2 2025, driven by the discontinuation of bexotegrast and workforce reductions. Operating expenses dropped 48% year-over-year.
-
Cash Runway Extended to H2 2028
Cash, equivalents, and short-term investments totaled $159.6M at June 30, 2026. Management believes this is sufficient to fund operations for at least the next 12 months and into the second half of 2028.
-
FORTIFY Trial Enrollment Ahead of Schedule
The Phase 1b trial of PLN-101095 in solid tumors is enrolling ahead of plan across three cohorts. Interim data is expected in 2027.
-
Biomarker Data Supports Oncology Pivot
Updated Phase 1 data presented at AACR showed PLN-101095 monotherapy triggered a coordinated T-cell reactivation cascade in responders, with increases in IFN-γ, CXCL9, and granzyme-B.
Analysis · PLRX · Life Sciences
Pliant's Q2 results show a sharply reduced net loss of $22.4M, down from $43.3M a year ago, driven by the wind-down of the failed bexotegrast program and restructuring. Cash of $159.6M now funds operations into the second half of 2028, removing near-term survival risk. The oncology pivot is gaining traction: enrollment in the FORTIFY Phase 1b trial of lead asset PLN-101095 is ahead of schedule, and new biomarker data presented at AACR strengthens the scientific rationale. An option repricing at $1.33 and an untapped $50M ATM provide additional financial flexibility. The stock trades near its 52-week low, so the extended runway and clinical progress are critical offsets to the company's challenged history.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1644 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PLRX was trading at $1.05 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $63.8M. The 52-week trading range was $1.03 to $1.95. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.